Regulation of smooth muscle cell function by CD44 in cardiovascular disease
CD44在心血管疾病中调节平滑肌细胞功能
基本信息
- 批准号:8051524
- 负责人:
- 金额:$ 41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-15 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAccountingActivation AnalysisAcuteAffectAngioplastyAnti-Inflammatory AgentsAnti-inflammatoryApolipoprotein EArterial Fatty StreakArteriesAtherosclerosisAttenuatedBindingBiologicalBlood VesselsBone MarrowC57BL/6 MouseCCND1 geneCD44 AntigensCD44 geneCardiovascular DiseasesCause of DeathCell CycleCell Cycle ProgressionCell ProliferationCell physiologyCellsChimera organismCoronaryCyclin D1Cyclin-Dependent KinasesDevelopmentEndothelial CellsEnvironmentEquilibriumEventExtracellular MatrixGeneticGlycosaminoglycansGuanosine TriphosphateHealthHyaluronanIn VitroInflammationInflammatoryInflammatory ResponseInjuryInterventionKnock-outKnockout MiceLigandsMediatingMitogensMolecular WeightMonitorMusMyocardial InfarctionNon-Steroidal Anti-Inflammatory AgentsPatientsPharmaceutical PreparationsPlayPreventionProceduresPublic HealthRegulationRiskRoleRuptureS PhaseSignal TransductionSiteSmooth Muscle MyocytesStentsTestingTherapeutic InterventionTimeTissuesUnited Statesatherogenesiscell growthcell typeimplantationin vivoinjuredminimally invasiveneointima formationnovelpreventresearch studyresponseresponse to injuryrestenosisselective expressionvascular smooth muscle cell proliferation
项目摘要
DESCRIPTION (provided by applicant): Proliferation of vascular smooth muscle cells (VSMCs) is fundamental to neointima formation, a hallmark of cardiovascular disease (CVD). The extracellular matrix (ECM) plays an important role in regulating VSMCs, and we have studied the effects of the ECM component hyaluronan (HA) and the HA receptor, CD44, on VSMC proliferation and neointima formation. We show that HA and CD44 have bifunctional effects on VSMC proliferation and activation. In vitro, the native high molecular weight form of HA (HMW-HA) antagonizes mitogen-induced S phase entry of VSMCs while the lower molecular weight forms of HA (LMW- HA) that accumulate at sites of inflammation synergize with mitogens to stimulate VSMC S phase entry. Both effects are mediated by CD44, and result from differential regulation of Rac- and ERK-dependent signaling to cyclin D1. HMW-HA binding to CD44 inhibits GTP-loading of Rac and Rac-dependent signaling to the cyclin D1 gene while LMW-HA binding to CD44 stimulates ERK-dependent cyclin D1 gene expression. A similar bifunctionality can be detected in vivo as genetic deletion of CD44 enhances the response to injury in C57BL/6 mice but inhibits atherogenesis in apoE-deficient mice. Since the ratio of LMW-HA to HMW-HA is directly related to the extent of inflammation, and the inflammatory environment is much greater in apoE-deficient mice as compared to B6 mice, we hypothesize that the biological response to CD44 in vivo is directed by the degree of local inflammation, and that changes in the inflammatory milieu can reconcile the seemingly contradictory effects of CD44 on VSMC activation and neointima formation during the response to vascular injury and atherogenesis. In Aim 1, we will compare the effects of CD44 on VSMC proliferation and neointima formation in vascular injury as we modulate inflammation, and we will exploit our recently developed floxed CD44 mouse to distinguish the effects of CD44 on SMCs and inflammatory cells. In Aim 2, we will perform similar experiments monitoring the effect of inflammation and cell type-specific CD44 expression on neointima formation during atherogenesis. In Aim 3, we will attempt to eliminate the bifunctional response of CD44 on VSMC activation by performing fine-wire injury on mice carrying an SMC-specific deletion of Rac1. PUBLIC HEALTH RELEVANCE: Cardiovascular disease due to atherosclerosis, the number one cause of death in the United States, is characterized by neointima formation due to inflammation and vascular smooth muscle cell proliferation. The balance between inflammation and formation of smooth muscle cell-rich fibrotic caps in part determines the risk to rupture of atherosclerotic plaques and acute events such as heart attacks. Minimally invasive percutaneous revascularization procedures such as angioplasty and stent implantation are currently considered the treatment of choice for the prevention and treatment of acute coronary events in many patients. However, such interventions are associated with a significant risk of vascular restenosis due to excessive vascular smooth cell proliferation in response to injury caused by the intervention. Modulating smooth muscle cell proliferation may be an important approach to minimize the risk of acute events in patients with atherosclerosis, and may also prevent restenosis following physical interventions, thereby greatly reducing the risks associated with standard therapeutic interventions. The proposed studies will define mechanisms that regulate smooth muscle cell growth and thus provide novel targets for treatment of atherosclerosis and restenosis.
描述(由申请方提供):血管平滑肌细胞(VSMC)的增殖是新生内膜形成的基础,是心血管疾病(CVD)的标志。细胞外基质(ECM)在调节VSMC中起着重要作用,我们研究了ECM组分透明质酸(HA)和HA受体CD 44对VSMC增殖和新生内膜形成的影响。我们发现HA和CD 44对VSMC增殖和活化具有双功能作用。在体外,天然高分子量形式的HA(HMW-HA)拮抗有丝分裂原诱导的VSMC的S期进入,而在炎症部位积累的较低分子量形式的HA(LMW-HA)与有丝分裂原协同作用以刺激VSMC S期进入。这两种效应都是由CD 44介导的,并且是由Rac和ERK依赖性信号传导至细胞周期蛋白D1的差异调节引起的。HMW-HA与CD 44的结合抑制了Rac和Rac依赖性信号传导至细胞周期蛋白D1基因的GTP负载,而LMW-HA与CD 44的结合刺激ERK依赖性细胞周期蛋白D1基因表达。在体内可以检测到类似的双功能性,因为CD 44的遗传缺失增强了C57 BL/6小鼠对损伤的反应,但抑制了apoE缺陷小鼠的动脉粥样硬化形成。由于LMW-HA与HMW-HA的比例与炎症程度直接相关,并且与B6小鼠相比,apoE缺陷小鼠的炎症环境要大得多,因此我们假设体内对CD 44的生物学反应是由局部炎症程度决定的,炎症环境的变化可以调和CD 44对VSMC活化和新生内膜形成的看似矛盾的作用。对血管损伤和动脉粥样硬化的反应。在目的1中,我们将比较CD 44对血管损伤中VSMC增殖和新生内膜形成的影响,因为我们调节炎症,我们将利用我们最近开发的floxed CD 44小鼠来区分CD 44对SMC和炎症细胞的影响。在目标2中,我们将进行类似的实验,监测动脉粥样硬化形成过程中炎症和细胞类型特异性CD 44表达对新生内膜形成的影响。在目标3中,我们将尝试通过对携带SMC特异性Rac 1缺失的小鼠进行细线损伤来消除CD 44对VSMC活化的双功能反应。公共卫生相关性:动脉粥样硬化引起的心血管疾病是美国的头号死因,其特征是炎症和血管平滑肌细胞增殖引起的新生内膜形成。炎症和富含平滑肌细胞的纤维化帽形成之间的平衡部分决定了动脉粥样硬化斑块破裂和急性事件如心脏病发作的风险。微创经皮血运重建术(如血管成形术和支架植入术)目前被认为是许多患者预防和治疗急性冠状动脉事件的首选治疗方法。然而,这种干预与血管再狭窄的显著风险相关,这是由于血管平滑肌细胞响应于由干预引起的损伤而过度增殖。调节平滑肌细胞增殖可能是最大限度降低动脉粥样硬化患者急性事件风险的重要方法,也可能预防物理干预后的再狭窄,从而大大降低与标准治疗干预相关的风险。拟议的研究将确定调节平滑肌细胞生长的机制,从而为动脉粥样硬化和再狭窄的治疗提供新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ellen Pure'其他文献
Ellen Pure'的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ellen Pure'', 18)}}的其他基金
The role of the stromal cell surface protease FAP in pancreatic cancer
基质细胞表面蛋白酶 FAP 在胰腺癌中的作用
- 批准号:
8511917 - 财政年份:2013
- 资助金额:
$ 41万 - 项目类别:
The role of the stromal cell surface protease FAP in pancreatic cancer
基质细胞表面蛋白酶 FAP 在胰腺癌中的作用
- 批准号:
8636413 - 财政年份:2013
- 资助金额:
$ 41万 - 项目类别:
The role of the stromal cell surface protease FAP in pancreatic cancer
基质细胞表面蛋白酶 FAP 在胰腺癌中的作用
- 批准号:
8786229 - 财政年份:2013
- 资助金额:
$ 41万 - 项目类别:
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
肺癌肿瘤微环境中的成纤维细胞激活蛋白
- 批准号:
7889926 - 财政年份:2010
- 资助金额:
$ 41万 - 项目类别:
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
肺癌肿瘤微环境中的成纤维细胞激活蛋白
- 批准号:
8214619 - 财政年份:2010
- 资助金额:
$ 41万 - 项目类别:
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
肺癌肿瘤微环境中的成纤维细胞激活蛋白
- 批准号:
8728438 - 财政年份:2010
- 资助金额:
$ 41万 - 项目类别:
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
肺癌肿瘤微环境中的成纤维细胞激活蛋白
- 批准号:
8045525 - 财政年份:2010
- 资助金额:
$ 41万 - 项目类别:
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
肺癌肿瘤微环境中的成纤维细胞激活蛋白
- 批准号:
8444543 - 财政年份:2010
- 资助金额:
$ 41万 - 项目类别:
Regulation of smooth muscle cell function by CD44 in cardiovascular disease
CD44在心血管疾病中调节平滑肌细胞功能
- 批准号:
8247826 - 财政年份:2009
- 资助金额:
$ 41万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别: